Pharmaceutical Services M&A Transactions

Fulcrum Therapeutics

Fulcrum Therapeutics and Slate Medicines merge, creating a new Nasdaq-listed biotech focused on migraine treatments, bolstered by $245 million in new funding.

LEO Pharma secures global rights to dersimelagon, a promising oral therapy for rare skin conditions EPP and XLP, in a deal valued up to $435 million.

Warburg Pincus exits Certified Group, a $300M revenue lab testing platform, to Mérieux NutriSciences in a strategic acquisition.

Valerio Therapeutics advances its €30 million acquisition of Etherna Immunotherapies, securing regulatory clearance and targeting a late August deal signing.

Jasper Therapeutics

Jasper Therapeutics merges with Kira Pharmaceuticals, enhancing its immunology pipeline with three key assets and securing $132 million in financing for extended operational runway.

Astorg establishes a new global diagnostics specialist by acquiring Thermo Fisher Scientific's microbiology division. Dirk Bontridder named CEO.

Wise Equity, via Wisequity VI, takes majority control of E-Pharma Trento, a specialized CDMO, from Unifarm. Strategic growth planned for nutraceuticals.